Advertisement
Singapore markets open in 3 hours 52 minutes
  • Straits Times Index

    3,343.35
    +11.65 (+0.35%)
     
  • S&P 500

    5,482.87
    +4.97 (+0.09%)
     
  • Dow

    39,164.06
    +36.26 (+0.09%)
     
  • Nasdaq

    17,858.68
    +53.53 (+0.30%)
     
  • Bitcoin USD

    61,420.45
    +419.19 (+0.69%)
     
  • CMC Crypto 200

    1,281.85
    +15.70 (+1.24%)
     
  • FTSE 100

    8,179.68
    -45.65 (-0.55%)
     
  • Gold

    2,338.60
    +25.40 (+1.10%)
     
  • Crude Oil

    81.82
    +0.92 (+1.14%)
     
  • 10-Yr Bond

    4.2880
    -0.0280 (-0.65%)
     
  • Nikkei

    39,341.54
    -325.53 (-0.82%)
     
  • Hang Seng

    17,716.47
    -373.46 (-2.06%)
     
  • FTSE Bursa Malaysia

    1,584.94
    -6.01 (-0.38%)
     
  • Jakarta Composite Index

    6,967.95
    -6,905.64 (-49.78%)
     
  • PSE Index

    6,390.58
    +77.47 (+1.23%)
     

Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways

Altimmune, Inc
Altimmune, Inc

GAITHERSBURG, Md., June 20, 2024 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Piper Sandler 2nd Annual Virtual Obesity Investor Day, being held on June 26, 2024, to discuss key takeaways from the American Diabetes Association’s (ADA) Scientific Sessions. Details on the fireside chat are as follows:

Title:

Piper Sandler Virtual Obesity Investor Day

 

 

Presenters:

Vipin Garg, Ph.D., Chief Executive Officer
Scott Roberts, Ph.D., Chief Scientific Officer

 

 

Date/Time:

Wednesday, June 26, 2024 at 9:30 a.m. EDT

 

The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.

ADVERTISEMENT

About Altimmune
Altimmune is a clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Company Contact:
Richard Eisenstadt
Chief Financial Officer
Phone: 240-654-1450
ir@altimmune.com

Investor Contacts:
Lee Roth
Burns McClellan
Phone: 646-382-3403
lroth@burnsmc.com
Julia Weilman
Burns McClellan
Phone: 646-732-4443
jweilman@burnsmc.com

Media Contact:
Danielle Cantey
Inizio Evoke Comms
Phone: 619-826-4657
Danielle.cantey@inizioevoke.com